XTX Topco Ltd Makes New $1.10 Million Investment in GSK plc (NYSE:GSK)

XTX Topco Ltd purchased a new stake in shares of GSK plc (NYSE:GSK) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 28,604 shares of the pharmaceutical company’s stock, valued at approximately $1,101,000.

Other large investors have also recently modified their holdings of the company. Register Financial Advisors LLC bought a new stake in GSK during the 1st quarter valued at about $31,000. Ashton Thomas Private Wealth LLC purchased a new position in GSK in the 2nd quarter worth approximately $37,000. Richardson Financial Services Inc. purchased a new stake in GSK during the 4th quarter valued at $40,000. PrairieView Partners LLC bought a new stake in shares of GSK in the 2nd quarter worth $47,000. Finally, Triad Wealth Partners LLC purchased a new position in shares of GSK in the second quarter worth $49,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GSK. Argus raised GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a research report on Thursday, June 20th. Barclays raised shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Finally, Jefferies Financial Group lifted their price objective on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $50.00.

GSK Trading Down 2.0 %

NYSE:GSK opened at $40.80 on Friday. GSK plc has a one year low of $33.67 and a one year high of $45.92. The business has a fifty day moving average price of $41.39 and a 200-day moving average price of $41.69. The firm has a market capitalization of $84.56 billion, a price-to-earnings ratio of 14.78, a price-to-earnings-growth ratio of 1.41 and a beta of 0.66. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, topping the consensus estimate of $1.00 by $0.09. The firm had revenue of $9.95 billion for the quarter, compared to the consensus estimate of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%. Sell-side analysts forecast that GSK plc will post 4.15 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be given a $0.3843 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 dividend on an annualized basis and a dividend yield of 3.77%. The ex-dividend date is Friday, August 16th. GSK’s dividend payout ratio is presently 54.71%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.